ACTOS LINKED TO INCREASED RISK OF BLADDER CANCER
Actos (pioglitazone), a drug used to treat Type 2 diabetes in adults, has been linked to bladder cancer in diabetics with exposure of more than one year.
In 2011 the U.S. Food and Drug Administration (FDA) issued a drug safety alert warning based on an ongoing study that use of Actos for more than one year may be associated with an increased risk of bladder cancer. The increased risk was noted in those patients with the longest exposure to the drug, and in those exposed to the highest cumulative dose of the drug.
Health authorities in France have suspended the use of Actos in France after a study suggested an increased risk of bladder cancer from Actos. In Germany, health authorities have made the recommendation to doctors that Actos not be used on new patients.
More recently, Health authorities in Canada issued a safety warning after an ongoing study of diabetic patients showed that diabetics who used Actos for more than one year had double the risk of developing bladder cancer than diabetic patients who did not use Actos. Even more short term use of Actos may increase the risk of bladder cancer, the study showed.
Hundreds of lawsuits have been filed in federal court and state courts around the country alleging injury from the use of Actos. The first bladder cancer trials have been tentatively scheduled. If you or a loved one have bladder cancer and have taken Actos for your Type 2 diabetes control, you may be entitled to compensation. Call us toll-free at (800) 500-5735 to receive a free consultation with one of our Actos lawyers, or complete our quick intake form on the right to receive a free case evaluation.